Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Search Results



Your search returned 1870 record(s).

Page 77 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:


  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
761 14.0 months Malignant pleural mesothelioma 4 Chemotherapy
Sotiria General Hospital Greece 1/2010
Treatment Details: Patients: This phase II study involved 62 malignant pleural mesothelioma patients who had not previously received chemotherapy. The median patient age was 66 years and 85.5% were male.
 
762 14.0 months Melanoma Cancer 4 Biologic therapy
Chemotherapy
University of California United States 4/2015
Treatment Details: Patients: This phase 2 study involved 38 BRAF wild-type melanoma patients, 68% of whom were male. No age information was provided. Treatment: Patients received biologic therapy with axi
 
763 13.9 months Advanced Melanoma 3 Biologic therapy
National Cancer Center Hospital Japan 7/2015
Treatment Details: Patients: This phase 1/2 study involved 11 melanoma patients who had the BRAFV600 mutation. The median patient age was 49 years and 3 were male. Treatment: Patients received biologic t
 
764 13.9 months Metastatic colorectal cancer 4 Chemotherapy
Hôpital Saint-Antoine France 4/2010
Treatment Details: Patients: This study involved 44 patients with metastatic colorectal cancer who had received previous chemotherapy with 5-FU, leucovorin, and oxaliplatin. The median patient age was 63 year
 
765 13.9 months Metastatic melanoma 4 Biologic therapy
Chemotherapy
Mayo Clinic United States 8/2012
Treatment Details: Patients: This phase 2 study involved previously untreated metastatic melanoma patients who were divided into two separate treatment groups. Group A consisted of 42 patients with a median
 
766 13.9 months BRAF-mutant metastatic melanoma 4 Biologic therapy
Chemotherapy
Institute Gustave Roussy France 6/2013
Treatment Details: Patients: This phase 2 study involved BRAF-mutant metastatic melanoma patients who were divided into two separate treatment groups. Group A consisted of 45 patients with a median age of 57
 
767 13.9 months Advanced urothelial cancer 4 Biologic therapy
Chemotherapy
Memorial Sloan-Kettering Cancer Center United States 1/2013
Treatment Details: Patients: This phase 2 study involved 51 advanced urothelial cancer patients who had not received prior systemic chemotherapy. The median patient age was 67 years and 72.5% were male. T
 
768 13.9 months Metastatic, castration-resistant prostate cancer 4 Biologic therapy
Chemotherapy
The Cancer Institute of New Jersey, UMDNJ-RWJMS United States 2/2010
Treatment Details: Patients: This phase II trial involved 63 men with metastatic castration-resistant prostate cancer that were separated into 2 separate studies (arms). Arm A involved 32 of the men with a m
 
769 13.8 months Unresectable hepatocellular carcinoma Chemotherapy
Federation Francophone de Cancerologie digestive France 3/2008
Treatment Details: Patients:  This phase III study involved 123 patients with unresectable hepatocellular carcinoma and liver cirrhosis.   Treatment:  Patients were treated with either transarterial lipiod
 
770 13.8 months hepatocellular carcinoma (advanced) 4 Chemotherapy
Hannover Medical School Germany 12/2005
Treatment Details: Patients: A total of 70 patients with advanced hepatocellular carcinoma were in enrolled in this phase II trial. Patients were divided into two groups of 35 each. Group A was comprised
 
Page 77 of 187  | Previous Page  | Next Page